[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-665398-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-665398-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","ich-guideline-q9-on-quality-risk-management-step-5","ICH guideline Q9 on quality risk management - Step 5","","ICH guideline Q9 on quality risk management, Step 5, presents principles and a structured process for applying quality risk management across pharmaceutical quality systems. It outlines responsibilities, initiating and conducting risk assessment, risk control, communication, and review, and describes a methodology for risk management implementation. The guideline supports integration into industry and regulatory operations, and includes definitions, references, and annexes listing practical risk management methods and potential applications across development, production, facilities, materials, laboratory controls, stability, packaging, and labelling.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ich-guideline-q9-on-quality-risk-management-step-5/665398/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ich-guideline-q9-on-quality-risk-management-step-5/665398.png","ImageObject",300,407,{"name":42,"@type":43},"DoDO","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-10-29",true,{"@type":52,"interactionType":53,"userInteractionCount":22},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the core purpose of ICH guideline Q9 on quality risk management (Step 5)?","Question",{"text":62,"@type":63},"It establishes principles and a general process to apply quality risk management effectively to protect patients by managing risks to quality within pharmaceutical quality systems.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How does the guideline structure the quality risk management process?",{"text":67,"@type":63},"It describes responsibilities and a sequence covering risk assessment, risk control, risk communication, and risk review, supported by defined methodology and integration considerations.",{"name":69,"@type":60,"acceptedAnswer":70},"What practical tools are included in the annexes?",{"text":71,"@type":63},"Annex I lists risk management methods and tools such as FMEA, FMECA, FTA, HACCP, HAZOP, PHA, risk ranking and filtering, and supporting statistical tools.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},665398,1793302355,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":103},962093270745,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","September 2015 EMA/CHMP/ICH/24235/2006  \nCommittee for Human Medicinal Products  \nICH guideline Q9 on quality risk management  \nStep 5  \n\n| Transmission to CHMP | June 2005 |\n| --- | --- |\n| Transmission to interested parties | June 2005 |\n| Deadline for comments | October 2005 |\n| Final adoption by CHMP | November 2005 |\n| Date for coming into effect | January 2006 |\n\nLink to: ICH Q8/Q9/Q10 Training material Link to: ICH Q8/Q9/Q10 Points to consider  \n30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5505 Send a question via our website [www.ema.europa.eu/contact](www.ema.europa.eu/contact)  \nAn agency of the European Union  \n© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged.  \nICH guideline Q9 on quality risk management  \nTable of contents  \n1. Introduction ............................................................................................ 3  \n2. Scope....................................................................................................... 3  \n3. Principles of quality risk management..................................................... 4  \n4. General quality risk management process ............................................... 4  \n4.1. Responsibilities ....................................................................................................5  \n4.2. Initiating a quality risk management process ...........................................................5  \n4.3. Risk assessment...................................................................................................5  \n4.4. Risk control .........................................................................................................6  \n4.5. Risk communication ..............................................................................................7  \n4.6. Risk review ..........................................................................................................7  \n5. Risk management methodology .............................................................. 7  \n6. Integration of quality risk management into industry and regulatory operations ................................................................................................... 8  \n7. Definitions ............................................................................................... 9  \n8. References ............................................................................................ 11  \nAnnex I: risk management methods and tools .......................................... 12  \nI.1 Basic risk management facilitation methods .......................................................... 12  \nI.2 Failure Mode Effects Analysis (FMEA) .................................................................... 12  \nI.3 Failure Mode, Effects and Criticality Analysis (FMECA) ............................................ 12  \nI.4 Fault Tree Analysis (FTA) .................................................................................... 13  \nI.5 Hazard Analysis and Critical Control Points (HACCP) ............................................... 13  \nI.6 Hazard Operability Analysis (HAZOP) .................................................................... 14  \nI.7 Preliminary Hazard Analysis (PHA) ....................................................................... 14  \nI.8 Risk ranking and filtering .................................................................................... 14  \nI.9 Supporting statistical tools .................................................................................. 15  \nAnnex II: Potential applications for quality risk management................... 15  \nII.1 Quality risk management as part of integrated quality management ....................... 15  \nII.2 Quality risk management as part of regulatory operations ..................................... 16  \nII.3 Quality risk management as part of","cbCaifztDdSpIF7Y","https://ap.wps.com/l/cbCaifztDdSpIF7Y","pdf",338580,"English","# 1. Introduction\n# 2. Scope\n# 3. Principles of quality risk management\n# 4. General quality risk management process\n## 4.1. Responsibilities\n## 4.2. Initiating a quality risk management process\n## 4.3. Risk assessment\n## 4.4. Risk control\n## 4.5. Risk communication\n## 4.6. Risk review\n# 5. Risk management methodology\n# 6. Integration of quality risk management into industry and regulatory operations\n# 7. Definitions\n# 8. References\n# Annex I: risk management methods and tools\n# Annex II: Potential applications for quality risk management","[{\"question\":\"What is the core purpose of ICH guideline Q9 on quality risk management (Step 5)?\",\"answer\":\"It establishes principles and a general process to apply quality risk management effectively to protect patients by managing risks to quality within pharmaceutical quality systems.\"},{\"question\":\"How does the guideline structure the quality risk management process?\",\"answer\":\"It describes responsibilities and a sequence covering risk assessment, risk control, risk communication, and risk review, supported by defined methodology and integration considerations.\"},{\"question\":\"What practical tools are included in the annexes?\",\"answer\":\"Annex I lists risk management methods and tools such as FMEA, FMECA, FTA, HACCP, HAZOP, PHA, risk ranking and filtering, and supporting statistical tools.\"}]","ICH guideline Q9 on quality risk management - Step 5 | PDF"]